Compositions comprising bacterial strains

A method of treating asthma in a subject in need thereof, comprising administering to the subject a pharmaceutical composition that comprises therapeutically effective amount of a bacteria strain:

• a. of species Roseburia hominis, wherein the Roseburia hominis bacteria strain comprises a 16S rRNA gene sequence with at least 95% sequence identity to SEQ ID NO:3, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a blocks substitution matrix (BLOSUM) of 62;
• or
• b. of species Roseburia cecicola, Roseburia faecis, or Roseburia inulinivorans that is a biotype of the Roseburia hominis bacteria strain.

A method of reducing an amount of an eosinophil in a tissue with increased eosinophils compared to normal tissue, comprising contacting the tissue with a pharmaceutical composition that comprises an amount of a bacteria strain of the genus Roseburia, wherein contacting is sufficient to reduce the amount of the eosinophil relative to an amount of the eosinophil prior to the contacting.

A method of treating a disorder in a subject in need thereof, comprising administering to the subject a pharmaceutical composition that comprises a therapeutically effective amount of a bacteria strain of the genus Roseburia, wherein the bacteria strain comprises a 16s rRNA gene sequence with at least 95% sequence identity to SEQ ID NO:3, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a blocks substitution matrix (BLOSUM) of 62.

A method of treating allergic asthma in a human subject in need thereof, comprising administering to the subject a pharmaceutical composition that comprises from about 1×103 to about 1×1011 CFU/g of a bacteria strain of species Roseburia hominis, with respect to a total weight of the pharmaceutical composition, wherein the Roseburia hominis bacteria strain comprises a 16s rRNA gene sequence with at least 95% sequence identity to SEQ ID NO:3, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a blocks substitution matrix (BLOSUM) of 62.

A pharmaceutical composition that comprises:

• a therapeutically effective amount of a Roseburia hominis bacteria strain and a pharmaceutically acceptable excipient, diluent, or carrier;
• wherein the bacteria strain comprises a 16s rRNA gene sequence with at least 95% sequence identity to SEQ ID NO:3, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a blocks substitution matrix (BLOSUM) of 62, and wherein the pharmaceutical composition is in dried form.